The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The influence of biliary drainage in patients with advanced pancreatic cancer receiving FOLFIRINOX.
 
Makoto Ueno
Honoraria - AstraZeneca; Lilly; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma; Yakult Honsha
Consulting or Advisory Role - Eisai
Research Funding - AstraZeneca; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Merck Serono; MSD; NanoCarrier; Ono Pharmaceutical; Shire; Taiho Pharmaceutical
 
Takeharu Yamanaka
Honoraria - Boehringer Ingelheim; Chugai Pharma; Taiho Pharmaceutical; Takeda
Research Funding - Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Takashi Ogura
No Relationships to Disclose
 
Atushi Yamaguchi
No Relationships to Disclose
 
Nobumasa Mizuno
Honoraria - Novartis; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Eisai; Novartis; Taiho Pharmaceutical
 
Masato Ozaka
Honoraria - Bayer; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Hideki Ueno
Honoraria - Taiho Pharmaceutical; Yakult Honsha
Research Funding - Lilly Japan (Inst); Merck Serono (Inst); OncoTherapy Science (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Kazuhiro Uesugi
No Relationships to Disclose
 
Noritoshi Kobayashi
No Relationships to Disclose
 
Hideyuki Hayashi
No Relationships to Disclose
 
Kentaro Sudo
No Relationships to Disclose
 
Naohiro Okano
Honoraria - Merck Serono; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); Baxalta/Shire (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); J-Pharma (Inst); Janssen (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD (Inst); NanoCarrier (Inst); Novartis (Inst); OncoTherapy Science (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst); Zeria Pharmaceutical (Inst)
 
Yosuke Horita
No Relationships to Disclose
 
Keiko Kamei
No Relationships to Disclose
 
Takafumi Hosokawa
Employment - Daiichi Sankyo
 
Toshiyuki Henmi
Employment - Yakult Honsha
 
Marina Kobayashi
No Relationships to Disclose
 
Akiko Todaka
Consulting or Advisory Role - Daiichi Sankyo; Taiho Pharmaceutical; Yakult Honsha
 
Akira Fukutomi
Honoraria - Daiichi Sankyo; Lilly Japan; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Yakult Honsha
Research Funding - NanoCarrier (Inst); Taiho Pharmaceutical (Inst); Teijin Pharma (Inst)